Skip to main content
SpringerLink
Log in
Book cover

Handbook of Insulin Therapies pp 55–82Cite as

Emerging Insulin Therapies

  • Chapter
  • First Online:

Abstract

Ultra-rapid-acting insulin formulations are currently in early development. Early studies suggest a more physiological prandial insulin action compared to currently available rapid-acting analogs (Table 3.1). They have the potential to benefit continuous subcutaneous insulin infusion (CSII) therapy and artificial closed-loop systems due to faster reaction times, allowing pump algorithms to dose insulin in real time. Earlier recombinant human insulin-based formulations have not yet received approval by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) and are currently undergoing development.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Krasner A. Safety and efficacy of ultra-rapid-acting human insulin formulation BIOD-123 in patients with type 1 diabetes. Webcast presented at 74th ADA Scientific Sessions, San Francisco; June 13-14, 2014.

    Google Scholar 

  2. Kaye J, Krasner A, Canney L, Pichotta P, Simms P, Krishnarajah J, et al. Novel formulations BIOD-238 and BIOD-250 result in more rapid absorption and declines from peak than Humalog. Poster presented at 74th ADA Scientific Sessions, San Francisco; June 13-14, 2014. Abstract 1028.

    Google Scholar 

  3. Anderson G, Alluis B, Meiffren G, Ranson A, Serousa C, Soula O, et al. The ultra-rapid biochaperone insulin lispro shows a faster onset of action and stronger early metabolic effect than insulin lispro alone. Poster presented at 50th EASD Scientific Sessions, Vienna; September 15-19th, 2014. Abstract 934.

    Google Scholar 

  4. Efficacy and safety of FIAsp compared to insulin aspart both in combination with insulin detemir in adults with type 1 diabetes (Onset 1). www.clinicaltrials.gov/ct2/show/NCT01831765. Accessed July 18, 2016.

  5. Hoevelmann U. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of BioChaperone Combo (BC Combo), the first fixed combination of glargine and lispro, in type 1 diabetes. Poster presented at 50th EASD Scientific Sessions, Vienna; September 15-19th, 2014. Poster 074.

    Google Scholar 

  6. Morrow L, Canney L, Pichotta P, Hompesch M, Krasner A, De Souza E. Concentrated insulin BIOD-531 is associated with accelerated onset of action compared to Humulin® U-500 and Humalog® Mix75/25™ and a basal duration profile. Poster presented at 74th ADA Scientific Sessions, San Francisco; June 13-17, 2014. Abstract 82-LB.

    Google Scholar 

  7. Bergenstal RM, Rosenstock RM, Arakaki RF, Prince MJ, Qu Y, Sinha VP, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, et al. Better glycemic control and weight loss with novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Garg S, Hideaki J, Dreyer M. Greater HbA1c reduction with basal insulin peglispro (BIL) vs insulin glargine (GL) in an open-label, randomized study in T1D patients (pts): IMAGINE 1. Presented at 75th American Diabetes Association (ADA) Scientific Sessions; June 5-9, 2015; Boston. Abstract 95-OR.

    Google Scholar 

  10. Bergenstal R, Lunt H, Franek E, Travert F, Mou J, Hartman ML, et al. Superior reduction of HbA1c in a double-blind, randomized study of basal insulin peglispro (BIL) vs insulin glargine (GL) in patients with T1D: IMAGINE 3. Presented at 75th American Diabetes Association (ADA) Scientific Sessions; June 5-9, 2015; Boston. Abstract 986-P.

    Google Scholar 

  11. Garg S, Selam J, Bhargava A, et al. HbA1c reduction and hypoglycemia with variable time (VT) and fixed time (FT) dosing of basal insulin peglispro (BIL) in type 1 diabetes (T1D): IMAGINE 7. Presented at 75th American Diabetes Association (ADA) Scientific Sessions: June 5-9, 2015; Boston. Abstract 1018-P.

    Google Scholar 

  12. Davies M, Russell-Jones D, Selam J, et al. Basal insulin peglispro (BIL) is superior to insulin glargine (GL) in reducing HbA1c at 52 wks in insulin-naïve T2D patients (Pts) treated with oral antihyperglycemic medications (OAMs): IMAGINE 2. Presented at 75th American Diabetes Association (ADA) Scientific Sessions; June 5-9, 2015; Boston. Abstract 93-OR.

    Google Scholar 

  13. Blevins T, Pieber T, Vega G, et al. Superior HbA1c reduction with basal insulin peglispro (BIL) vs insulin glargine (GL) and preprandial insulin lispro in a double-blind study in patients (Pts) with type 2 diabetes (T2D): IMAGINE 4. Presented at 75th American Diabetes Association (ADA) Scientific Sessions; June 5-9, 2015; Boston. Abstract 985-P.

    Google Scholar 

  14. Buse J, Rodbard H, Serrano C, et al. Superior HbA1c reduction with basal insulin peglispro (BIL) vs insulin glargine (GL) alone or with oral antihyperglycemic medications (OAMs) in T2D patients (pts) previously treated with basal insulin: IMAGINE 5. Presented at 75th American Diabetes Association (ADA) Scientific Sessions; June 5-9, 2015; Boston. Abstract 984-P.

    Google Scholar 

  15. Grunberger G, Chen L, Rodriguez Á, et al. Basal insulin peglispro (BIL) provides clinically and significantly better HbA1c control with less nocturnal hypoglycemia than NPH when used in combination with oral agents in insulin-naïve T2D patients (pts): IMAGINE 6. Presented at 75th American Diabetes Association (ADA) Scientific Sessions; June 5-9, 2015; Boston. Abstract 1004-P.

    Google Scholar 

  16. Riddle MC, Bolli GB, Zieman M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–62.

    Article  CAS  PubMed  Google Scholar 

  17. Home PD, Bergenstal RM, Bolli GB, Zieman M, Rojeski M, Espinasse M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38:2217–25.

    Article  CAS  PubMed  Google Scholar 

  18. Matsuhisa M, Koyama M, Cheng XN, Shimizu S, Hirose T. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1). Diabetes. 2014;63(suppl 1A):LB22.

    Google Scholar 

  19. Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–43.

    Article  PubMed  Google Scholar 

  20. Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Terauchi Y, Koyama M, Cheng X, Shimizu S, Takahisa H; EDITION JP 2 Study Group. Glycaemic control and hypoglycaemia in Japanese people with T2DM receiving new insulin glargine 300 U/ml in combination with OADs (EDITION JP 2). Diabetologia. 2014;57(suppl 1):S401. Abstract 95-LB.

    Google Scholar 

  22. Ritzel R, Roussel R, Bolli GB, Vinet L, Yki-Jarvinen H. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in a meta-analysis of Phase 3a EDITION clinical trials in people with T2DM. Can J Diabetes. 2014;38:S2–24.

    Google Scholar 

  23. Gough SCL, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–93.

    Article  CAS  PubMed  Google Scholar 

  24. Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37:2926–33.

    Article  CAS  PubMed  Google Scholar 

  25. Rosenstock J, Diamant M, Silvestre L, Souhami E, Zhou T, Fonseca V, et al. Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs. glargine in type 2 diabetes inadequately controlled on metformin. Poster resented at the European Association for the Study of Diabetes annual meeting, Vienna, September 15-19th, 2014. Abstract 241.

    Google Scholar 

  26. Bode BW, Lorber DL, Gross J, et al. Reduced hypoglycemia risk with an inhaled insulin compared to injected prandial insulin in type 1 diabetes. Webcast presented at 74th American Diabetes Association Scientific Sessions; June 13-17, 2014; San Francisco.

    Google Scholar 

  27. Tack CJ, Christov V, de Galan BE, Derwahl KM, Klausmann G, Pelikánová T, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47–57.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal glargine versus daily biaspart insulin for type 2 diabetes: a multicentric randomised trial. Lancet. 2010;375:2244–53.

    Article  CAS  PubMed  Google Scholar 

  29. Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, et al. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes. 2002;51:1663–71.

    Article  CAS  PubMed  Google Scholar 

  30. Neutel J, Kidron M, Arbit E, Homer K. Bedtime oral insulin lowers fasting blood glucose levels in T2DM patients. American Diabetes Association 74th Scientific Sessions; June 6–9, 2014; San Francisco. Abstract 87-LB.

    Google Scholar 

  31. Eldor R, Corcos A, Arbit E, Kidron M. Concomitant oral and subcutaneous insulin therapy toward stabilization of uncontrolled Type 1 Diabetes Mellitus (T1DM). Presented at Diabetes Technology Meeting, Bethesda, MD. November 8-10, 2012. www.oramed.com/wp-content/uploads/2015/01/DT2012.pdf. Accessed July 18, 2016.

  32. Khedkar A, Iyer H, Anand A, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab. 2010;12:659–64.

    Article  CAS  PubMed  Google Scholar 

  33. Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab. 2010;12:82–7.

    Article  CAS  PubMed  Google Scholar 

  34. Broke-Smith TP, Luzio SD, Lockett A, New RCC, Owens DR. Repeat-dosing of oral insulin (Capsulin) in persons with type 2 diabetes [Abstract]. Diabetologia. 2008;Suppl 1:S1–588.

    Google Scholar 

  35. Geho WB, Rosenberg LN, Schwartz SL, Lau JR, Gana TJ. A single-blind, placebo-controlled, dose-ranging trial of oral hepatic directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2014;8:551–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Morçöl T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJ. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int J Pharm. 2004;277:91–7.

    Article  PubMed  Google Scholar 

  37. Pozzilli P, Manfrini S, Costanza F, Coppolino G, Cavallo MG, Fioriti E, et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism. 2005;54:930–4.

    Article  CAS  PubMed  Google Scholar 

  38. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial effects of addition of oral spray insulin on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther. 2004;6:1–8.

    Article  CAS  PubMed  Google Scholar 

  39. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis. 2010;10:90.

    Article  CAS  Google Scholar 

  40. Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogs. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline. Accessed July 18, 2016.

  41. Food and Drug Administration (FDA). Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. Food and Drug Administration, 2012. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. Accessed July 18, 2016.

  42. World Health Organization (WHO). Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Press 2009. www.who.int/biologicals/areas/biological_therapeutics. Accessed July 18, 2016.

  43. Olsen K. Alliance for Safe Biologics Medicines European Prescribers Survey. 2014. ASBM website. http://safebiologics.org/resource/wp-content/uploads/2014/03/ASBM-EUROPEAN-PHYSICIANS-SURVEY-ON-BIOSIMILARS-Ex-summary.pdf. Accessed July 18, 2016.

  44. Blevins T, Dahl D, Rosenstock J, et al. Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study. Presented at 74th American Diabetes Association (ADA) Scientific Sessions; June 13-17, 2014; San Francisco. Abstract 69-OR.

    Google Scholar 

  45. Rosenstock J, Hollander P, Bhargava L, et al. Similar efficacy and safety with LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with T2DM: The ELEMENT 2 Study. Presented at 74th American Diabetes Association (ADA) Scientific Sessions; June 13-17, 2014; San Francisco.

    Google Scholar 

  46. Verma M, Hazra P, Iyer H, et al. Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Countries. 2011;31:26–31.

    Article  CAS  Google Scholar 

  47. European Medicines Agency. Pre-authorisation Evaluation of Medicines for Human Use. Withdrawal Assessment Report for Insulin Human Rapid Marvel. London: EMEA, 2008. Document reference: EMEA/CHMP/317778/2007. www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500067086.pdf. Accessed July 18, 2016.

  48. A phase III clinical trial to study the safety and efficacy of MK-1293 compared to Lantus™ in subjects with type 1 diabetes. https://clinicaltrials.goc/ct2/NCT02059161. Accessed July 18, 2016.

Further Reading

  • Berger M. Oral insulin 1922–1992: the history of continuous ambition and failure. In: Berger M, Gries FA, editors. Frontiers in insulin pharmacology. Stuttgart: Thieme Publishing Group; 1993:144–8.

    Google Scholar 

  • Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and new insulin regimens: a review of their role in improving glycemic control in patients with diabetes. Postgrad Med J. 2009;85:257–67.

    Article  CAS  PubMed  Google Scholar 

  • Heller S, Kozlovski P, Kurtzhals P. Insulin’s 85th anniversary—an enduring medical miracle. Diabetes Res Clin Pract. 2007;78:149–58.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. George Eliot Hospital NHS Trust, Nuneaton, United Kingdom

    Winston Crasto

  2. Leicester Diabetes Centre, Leicester General Hospital, Leicester, United Kingdom

    Janet Jarvis & Melanie J. Davies

Authors
  1. Winston Crasto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet Jarvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melanie J. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Crasto, W., Jarvis, J., Davies, M.J. (2016). Emerging Insulin Therapies. In: Handbook of Insulin Therapies. Adis, Cham. https://doi.org/10.1007/978-3-319-10939-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-10939-8_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-10938-1

  • Online ISBN: 978-3-319-10939-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation